Sonoma Pharmaceuticals (SNOA) Shares Outstanding (Diluted Average) (2013 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly Shares Outstanding (Diluted Average) of $1.7 million in Q4 2025, up 1.28% quarter-over-quarter from $1.6 million in Q3 2025, and up 13.87% on a YoY basis from $1.5 million in Q4 2024.
Sonoma Pharmaceuticals (SNOA) Shares Outstanding (Diluted Average) (2013 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Shares Outstanding (Diluted Average) history runs 13 years deep, the most recent figure standing at $1.7 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Diluted Average) rose 13.87% year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.7 million (up 13.87% YoY), while the FY2025 annual figure was $1.2 million, up 172.75% from the prior year.
- Shares Outstanding (Diluted Average) was $1.7 million for Q4 2025 at Sonoma Pharmaceuticals, up from $1.6 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $4.9 million in Q2 2023 to a low of $2344.0 in Q3 2021.
- Historically, Shares Outstanding (Diluted Average) has averaged $1.3 million across 5 years, with a median of $1.0 million in 2024.
- The sharpest annual moves came in 2021 and 2023: Shares Outstanding (Diluted Average) plunged 99.89% in 2021, then surged 159074.46% in 2023.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $3080.0 in 2021, then surged by 100776.62% to $3.1 million in 2022, then tumbled by 88.7% to $351000.0 in 2023, then soared by 317.09% to $1.5 million in 2024, then grew by 13.87% to $1.7 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $1.7 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 1.18 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 422.40 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 47.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 103.40 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 506.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 228.36 Mn |
| 10 | Sonoma Pharmaceuticals | 1.90 Mn | -659,569.98 | 1.65 Mn | 1.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 851,000.00 |
| Mar 31, 2024 | 455,000.00 |
| Dec 31, 2023 | 351,000.00 |
| Sep 30, 2023 | 258,000.00 |
| Jun 30, 2023 | 4.94 Mn |
| Mar 31, 2023 | 3.39 Mn |
| Dec 31, 2022 | 3.11 Mn |
| Sep 30, 2022 | 3,101.00 |
| Jun 30, 2022 | 3,101.00 |
| Mar 31, 2022 | 2,653.00 |
| Dec 31, 2021 | 3,080.00 |
| Sep 30, 2021 | 2,344.00 |
| Jun 30, 2021 | 2.09 Mn |
| Dec 31, 2020 | 1,967.00 |